日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Causes of death in patients with locally advanced head and neck cancer treated with radiotherapy and systemic therapy

接受放射治疗和全身治疗的局部晚期头颈癌患者的死亡原因

Zapata, I; Alvarez, M; Hidalgo, R; Pajares, B; Garcia-Anaya, M J; Toledo, M D; Trigo, J M; Lupiañez-Perez, Y; Medina, J A; Jaime Gomez-Millan, J

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)

SEOM非小细胞肺癌治疗临床指南(2018)

Majem, M; Juan, O; Insa, A; Reguart, N; Trigo, J M; Carcereny, E; García-Campelo, R; García, Y; Guirado, M; Provencio, M

Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy

pMEK的亚细胞定位与接受同步放化疗的局部晚期头颈癌的预后不同

Gomez-Millan, J; Pajares, B; Perez-Villa, L; Carnero, A; Alvarez, M; De Luque, V; Rivas, F; Trigo, J M; Toledo, M D; Alba, E; Medina, J A

Screening Medications for the Treatment of Cannabis Use Disorder

筛选用于治疗大麻使用障碍的药物

Panlilio, L V; Justinova, Z; Trigo, J M; Le Foll, B

Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)

西班牙肿瘤内科学会(SEOM)关于口服药物治疗癌症的立场声明

Colomer, R; Alba, E; González-Martin, A; Paz-Ares, L; Martín, M; Llombart, A; Rodríguez Lescure, Á; Salvador, J; Albanell, J; Isla, D; Lomas, M; Rodríguez, C A; Trigo, J M; Germà, J R; Bellmunt, J; Tabernero, J; Rosell, R; Aranda, E; Cubedo, R; Baselga, J

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.

一项针对实体瘤的血管生成抑制剂 SU5416(semaxanib)的 I 期研究,纳入了动态对比 MR 药效学终点

O'Donnell A, Padhani A, Hayes C, Kakkar A J, Leach M, Trigo J M, Scurr M, Raynaud F, Phillips S, Aherne W, Hardcastle A, Workman P, Hannah A, Judson I

[Main parameters of lung function in chronic obstructive pulmonary disease (COPD)]

【慢性阻塞性肺疾病(COPD)肺功能主要参数】

Marín Trigo, J M